pentostatin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 76 Diseases   5 Trials   5 Trials   414 News 


«123456»
  • ||||||||||  pentostatin / Generic mfg.
    Journal:  Activation of 6-Alkoxy-Substituted Methylenecyclopropane Nucleoside Analogs Requires Enzymatic Modification by Adenosine Deaminase-Like Protein 1. (Pubmed Central) -  Aug 4, 2020   
    To test this hypothesis, pentostatin (deoxycoformycin [dCF]), an adenosine deaminase-like protein 1 (ADAL-1) inhibitor, was coincubated with MBX-2168...Purified ADAL-1 demonstrated time-dependent removal of the moiety on the guanine ring of MBX-2168-MP with a K = 17.5 ± 2.4 μM and a V = 0.12 ± 0.04 nmol min Finally, synguanol-TP demonstrated concentration-dependent inhibition of HSV-1 UL30 and HCMV UL54 with ICs of 0.33 ± 0.16 and 0.38 ± 0.11 μM, respectively. We therefore conclude that ADAL-1 is the enzyme responsible for removing the moiety from the guanine ring of MBX-2168-MP prior to conversion to a triphosphate, the active compound that inhibits the viral DNA polymerase.
  • ||||||||||  pentostatin / Generic mfg.
    Journal:  Characterization of the coformycin biosynthetic gene cluster in Streptomyces kaniharaensis. (Pubmed Central) -  Aug 1, 2020   
    Coformycin and pentostatin are structurally related N-nucleoside inhibitors of adenosine deaminase characterized by an unusual 1,3-diazepine nucleobase...CofB also shows activation by adenosine triphosphate (ATP) despite the reaction requiring neither a phosphorylated nor an adenylated intermediate. This may serve to help regulate metabolic partitioning between the l-histidine and coformycin pathways.
  • ||||||||||  Leustatin (cladribine) / J&J, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Journal, IO Biomarker:  No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant. (Pubmed Central) -  Apr 16, 2020   
    HCL and HCLv are uncommon lymphoid neoplasms that lead to a characteristic constellation of symptoms. The emergence of PAs and novel targeted agents have improved the likelihood and durability of responses for these patients.
  • ||||||||||  dexamethasone / Generic mfg., pentostatin / Generic mfg.
    Clinical, Journal:  Immune recovery uveitis in a patient with herpes retinitis as a complication of hairy cell leukaemia. (Pubmed Central) -  Apr 12, 2020   
    A 51 year-old man with hairy cell leukaemia was treated with pentostatin...The patient was treated with 2-monthly retro-septal injections of triamcinolone, oral corticosteroids, intravitreal dexamethasone implants and, finally, pars plana vitrectomy...Pars plana vitrectomy may be necessary. Ophthalmologists should be alert to the possibility of immune recovery uveitis in HIV negative patients.
  • ||||||||||  Leustatin (cladribine) / J&J, Lumoxiti (moxetumomab pasudotox) / AstraZeneca, Innate, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Journal:  Moxetumomab pasudotox for the treatment of hairy cell leukemia. (Pubmed Central) -  Apr 1, 2020   
    The drug has been approved in 2018 by the FDA for the treatment of patients with relapsed/refractory HCL who had at least two prior systemic therapies including at least one purine nucleoside analog. Expert opinion: The use of moxetumomab pasudotox is a promising new strategy for the treatment of HCL.
  • ||||||||||  pentostatin / Generic mfg.
    Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant (World Center Marriott - Palms & Cypress Foyers) -  Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_1125;    
    Due to the small number of autoSCT with positive PET-CT scans, BM biopsy, or PB flow at the time of SCT, no association between the above-mentioned variables and relapse was identified. Further studies with larger numbers of pts are warranted to determine the role of pre-autoSCT PET-CT, BM and PB flow as prognostic factors in T-NHL.
  • ||||||||||  pentostatin / Generic Mfg.
    Preclinical, Journal:  Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms. (Pubmed Central) -  Dec 6, 2019   
    The aim of this study was to test the effects of adenosine deaminase inhibition by 2'deoxycoformycin (dCF) on the breast cancer development...This study highlights beneficial effects of adenosine deaminase inhibition on breast cancer development. The inhibition of adenosine deaminase activity by dCF reduced tumour size that was closely related to the decreased aggressiveness of tumour cells by adenosine receptor-dependent mechanisms and endothelial protection.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, fluconazole / Generic mfg., Rituxan (rituximab) / Roche, Biogen
    Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_2994;    
    In this retrospective analysis of CLL patients, treatment for CLL significantly increased the rate of fungal infections, primarily candida and aspergillus. Further study is needed to understand the effect of modern treatments on fungal infections in CLL.
  • ||||||||||  Campath (alemtuzumab) / Sanofi
    No Improvement in Survival for T-PLL Patients over the Last Two Decades (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_2383;    
    Mean age at diagnosis was 61 years old (range 32-88) and M: F ratio was ~2:1 (113:61). 90 patients had reliable information on complete blood count (CBC) at diagnosis with median white blood cell count of 74 x 109/L (range 10-918), median hemoglobin 126 g/L (range 59-175) and median platelet count 116 x 109/L (range 7-513).
  • ||||||||||  Leustatin (cladribine) / J&J, Rituxan (rituximab) / Roche, Biogen
    Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Retrospective Single-Institution Analysis (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_2372;    
    The addition of R may improve the PFS in patients with HCL in the first and 2nd -line settings however a longer follow up is needed. A recently described prospective randomized trial in the use of concomitant rituximab plus PNA has reported a higher MRD free CR in comparison with PNA alone but not PFS yet.
  • ||||||||||  Leustatin (cladribine) / J&J
    French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_2367;    
    Introduction: Hairy-cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder with a favorable outcome thanks to treatment with purine analogues (PNA) like cladribine and pentostatin. In this updated real-world retrospective cohort with a long follow-up and most pts treated with PNA, we highlighted the importance and the excess of second cancers in HCL patients, in particular hematological malignancies.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Leustatin (cladribine) / J&J, Darzalex IV (daratumumab) / J&J
    Automated Electronic Notification of Medications Report Enhances Transfusion Safety (Exhibit Hall 2-3 - Henry B. Gonzalez Convention Center) -  Sep 20, 2019 - Abstract #AABB2019AABB_77;    
    Providers may fail to order irradiated products when indicated. Real time knowledge of interfering drugs optimizes testing.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Journal, CAR T-Cell Therapy:  Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. (Pubmed Central) -  Aug 1, 2019   
    Here we report the use of CD19-targeted CAR T cells incorporating the intracellular signaling domain of CD28 (19-28z) as a consolidative therapy in 8 patients with residual CLL following first-line chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab...CAR T cells were detectable post-infusion in 4 patients, with a longest observed persistence of 48 days by qPCR. Further strategies to enhance CAR T cell efficacy in CLL are under investigation.
  • ||||||||||  SS1(dsFv)-PE38 / AstraZeneca
    Trial completion:  SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma (clinicaltrials.gov) -  Jun 6, 2019   
    P1/2,  N=55, Completed, 
    Further strategies to enhance CAR T cell efficacy in CLL are under investigation. Active, not recruiting --> Completed
  • ||||||||||  cordycepin (OVI-123) / OncoVista
    Journal:  Cordycepin (3'-deoxyadenosine) and pentostatin (deoxycoformycin) against Trypanosoma cruzi. (Pubmed Central) -  Apr 23, 2019   
    In vivo, the combined use of cordycepin and pentostatin did not show the expected curative effect, however it was able to control the parasitema in the peak period. In summary, the combination of cordycepin and pentostatin showed no curative effect in mice infected by T. cruzi, despite the in vitro reduction of epimastigotes and trypomastigotes.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial initiation date:  A Blood Stem Cell Transplant for Sickle Cell Disease (clinicaltrials.gov) -  Dec 19, 2018   
    P1,  N=6, Recruiting, 
    The high overall and complete response levels in favorable genetic risk CLL along with favorable toxicity profiles provide rationale for consideration of a PC based strategy for previously untreated progressive CLL. Initiation date: Sep 2018 --> Jun 2019
  • ||||||||||  Journal:  Update on hairy cell leukemia. (Pubmed Central) -  Sep 28, 2018   
    Rituximab has limited activity as a single agent but achieves high complete remission rates without minimal residual disease when combined with purine analogues, albeit with chemotherapy-associated toxicity. Investigational nonchemotherapy options include moxetumomab pasudotox, which targets CD22; vemurafenib or dabrafenib, each of which targets the BRAF V600E protein; trametinib, which targets mitogen-activated protein kinase enzyme (MEK); and ibrutinib, which targets Bruton tyrosine kinase (BTK).
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial initiation date:  A Blood Stem Cell Transplant for Sickle Cell Disease (clinicaltrials.gov) -  Jul 13, 2018   
    P1,  N=6, Recruiting, 
    Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Initiation date: Jun 2018 --> Sep 2018
  • ||||||||||  cladribine / Generic mfg.
    Clinical, Review, Journal:  Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. (Pubmed Central) -  Jul 12, 2018   
    In an analysis of a larger cohort of unselected patients in the Surveillance, Epidemiology, and End Results (SEER) database, we found that mortality rates for patients with HCL were similar to those of the general population approximately 5 years after diagnosis. These data confirm the excellent prognosis for patients with HCL after first- and second-line PNA therapy.